Replies to post #107624 on Anavex Life Sciences Corp (AVXL)

[A_Good_Day_2]

I don't think there is much likelihood of a partnership having been settled since the Bloomberg interview this week.

And as Bourbon said, patent news will almost definitely not be discussed.

The only thing I'm wondering about is that the announcement about tomorrow's presentation said it will be streamed live and then archived on Anavex.com. Tomorrow morning there should be a PR in the premarket if there is anything coming. I'm not holding my breath though.

[falconer66a]

Well said. The science not a factor.

Those of us who have studied and understand the revolutionary new biochemistry of the Anavex molecules, and how they will revolutionize 21st-century even more than antibiotics did in the last century continue to ponder the continuing ridiculously low share price range of AVXL. What's the deal?

It's clearly this. For retail stock buyers, the unique biochemistry is some pretty complicated "brain science," understood only by brain scientists; beyond the man on the street trying to conduct due diligence.

Institutional buyers, hedge funds, mutual funds, and the like also discount or fail to understand the science. Lots and lots of science for lots and lots of both new and old pharmaceutical companies. Pure science never elevates share prices. Only FDA drug approvals and consequent drug sales do that. Institutional buyers look only for information telling of such regulatory and sales developments. The science be damned. The ability to profitably sell shares and drugs are the only controlling factors being assessed.

So, until Missling or the company can tell some news related to future sales --- such as positive Rett or Alzheimer's trial results --- AVXL share prices will continue to trade in a narrow range; perhaps even trending downward. Projected and anticipated $$$ will be in control, not understandings or applications of the authentic underlying science.